The FTC analyzed data for 51 specialty generic drugs dispensed from 2017-2022 for patients with commercial insurance or Medicare Part D plans managed by CVS Caremark, Express Scripts and OptumRx.
The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
The FTC called out the nation’s leading pharmacy benefit managers for inflating pharmacy costs, affecting both employers and ...
A new FTC report found that pharmacy benefit managers have inflated the price of life-saving generic prescription drugs, ...
In the lawsuit, AG Gentner Drummond outlined 200 individual prescription claims that were reimbursed below acquisition cost ...
A yearslong Federal Trade Commission probe, resulting in a report released in July, reported that of the six pharmacy benefit ...
Attorney General Gentner Drummond sued CVS Caremark in an Oklahoma administrative court alleging that the company is under ...
At least one Woodward pharmacist is celebrating an action by Oklahoma Attorney General Gentner Drummond that could turn the ...
The FTC’s findings—which analyzed 51 specialty generic drugs from 2017 to 2022—showed these pharmacy benefit managers’ (PBMs') affiliated pharmacies spun up $7.3 billion in excess revenue ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback